Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Short term Debt (2016 - 2022)

Historic Short term Debt for Marker Therapeutics (MRKR) over the last 6 years, with Q4 2022 value amounting to $2.5 million.

  • Marker Therapeutics' Short term Debt changed N/A to $2.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2022, which is N/A changed from last year.
  • As of Q4 2022, Marker Therapeutics' Short term Debt stood at $2.5 million.
  • Over the past 5 years, Marker Therapeutics' Short term Debt peaked at $8.0 million during Q2 2022, and registered a low of $8000.0 during Q1 2018.
  • In the last 3 years, Marker Therapeutics' Short term Debt had a median value of $107000.0 in 2018 and averaged $1.5 million.
  • As far as peak fluctuations go, Marker Therapeutics' Short term Debt soared by 168333.33% in 2018, and later crashed by 5578.23% in 2019.
  • Quarter analysis of 3 years shows Marker Therapeutics' Short term Debt stood at $49000.0 in 2018, then tumbled by 36.73% to $31000.0 in 2019, then surged by 7964.52% to $2.5 million in 2022.
  • Its Short term Debt was $2.5 million in Q4 2022, compared to $5.0 million in Q3 2022 and $8.0 million in Q2 2022.